Published online before print September 7, 2004, doi: 10.1161/01.CIR.0000142046.58632.3A
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:1542-1548.)
© 2004 American Heart Association, Inc.
Congenital Heart Disease |
Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease
From the Divisions of Cardiology (E.T.J., J.S., L.K.H.) and Rheumatology (E.D.S.), Department of Pediatrics, The Hospital for Sick Children, and the Fetal Medicine Unit (G.R.), Mount Sinai Hospital, University of Toronto, Toronto; and the Division of Cardiology, Department of Pediatrics, Sainte-Justine Hospital, University of Montreal, Montreal (J.C.F.), Canada. Dr Hornberger is now at the University of California, San Francisco Children’s Hospital, Department of Pediatrics, Division of Cardiology, The Fetal Cardiac Program, San Francisco, Calif.
Correspondence to Edgar T. Jaeggi, MD, Director, Fetal Cardiology, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G 1X8, Canada. E-mail edgar.jaeggi{at}sickkids.ca
Received November 25, 2003; de novo received April 10, 2004; revision received May 17, 2004; accepted May 18, 2004.
Background— Untreated isolated fetal complete atrioventricular block (CAVB) has a significant mortality rate. A standardized treatment approach, including maternal dexamethasone at CAVB diagnosis and ß-stimulation for fetal heart rates <55 bpm, has been used at our institutions since 1997. The study presents the impact of this approach.
Methods and Results— Thirty-seven consecutive cases of fetal CAVB since 1990 were studied. Mean age at diagnosis was 25.6±5.2 gestational weeks. In 33 patients (92%), CAVB was associated with maternal anti-Ro/La autoantibodies. Patients were separated into those diagnosed between 1990 and 1996 (group 1; n=16) and those diagnosed between 1997 and 2003 (group 2; n=21). The 2 study groups were comparable in the clinical presentation at CAVB diagnosis but did differ in prenatal management (treated patients: group 1, 4/16; group 2, 18/21; P<0.0001). Overall, 22 fetuses were treated, 21 with dexamethasone and 9 with ß-stimulation for a mean of 7.5±4.5 weeks. Live-birth and 1-year survival rates of group 1 were 80% and 47%, and these improved to 95% for group 2 patients (P<0.01). The 21 patients treated with dexamethasone had a 1-year survival rate of 90%, compared with 46% without glucocorticoid therapy (P<0.02). Immune-mediated conditions (myocarditis, hepatitis, cardiomyopathy) resulting in postnatal death or heart transplantation were significantly more common in untreated anti-Ro/La antibody–associated pregnancies compared with patients treated with steroids (0/18 versus 4/9 live births; P=0.007).
Conclusions— A standardized treatment approach, including transplacental fetal administration of dexamethasone and ß-stimulation at heart rates <55 bpm, reduced the morbidity and improved the outcome of isolated fetal CAVB.
Key Words: heart block • fetus • cardiotonic agents • steroids • pregnancy
Related Article:
Circulation 2004 110: 1513.
This article has been cited by other articles:
 |
|
 |
|
  J. Frankovich, C. Sandborg, P. Barnes, S. Hintz, and E. Chakravarty Neonatal Lupus and Related Autoimmune Disorders of Infants NeoReviews, May 1, 2008; 9(5): e206 - e217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Skog, M. Wahren-Herlenius, B. Sundstrom, K. Bremme, and S.-E. Sonesson Outcome and Growth of Infants Fetally Exposed to Heart Block-Associated Maternal Anti-Ro52/SSA Autoantibodies Pediatrics, April 1, 2008; 121(4): e803 - e809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhao, B. F. Cuneo, J. F. Strasburger, J. C. Huhta, N. L. Gotteiner, and R. T. Wakai Electrophysiological characteristics of fetal atrioventricular block. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K. Hornberger and K. Collins New insights into fetal atrioventricular block using fetal magnetocardiography. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 85 - 86. [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Gardiner, C. Belmar, L. Pasquini, A. Seale, M. Thomas, W. Dennes, M. J O Taylor, E. Kulinskaya, and R. Wimalasundera Fetal ECG: a novel predictor of atrioventricular block in anti-Ro positive pregnancies Heart, November 1, 2007; 93(11): 1454 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. K Hornberger and D. J Sahn Rhythm abnormalities of the fetus Heart, October 1, 2007; 93(10): 1294 - 1300. [Full Text] [PDF]
|
|
|
|
 |
|
 P.A. Gordon Review: Congenital heart block: clinical features and therapeutic approaches Lupus, August 1, 2007; 16(8): 642 - 646. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Tincani, C. B. Rebaioli, M. Taglietti, and Y. Shoenfeld Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus Rheumatology, October 1, 2006; 45(suppl_4): iv8 - iv13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Saar, W. Hermann, and U. Muller-Ladner Connective tissue diseases and pregnancy Rheumatology, October 1, 2006; 45(suppl_3): iii30 - iii32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N Costedoat-Chalumeau, S Georgin-Lavialle, Z Amoura, and J-C Piette Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block Lupus, September 1, 2005; 14(9): 660 - 664. [Abstract] [PDF]
|
|
|
|
|
|
T. P. Graham Jr The Year in Congenital Heart Disease J. Am. Coll. Cardiol., June 7, 2005; 45(11): 1887 - 1899. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rosenthal, P. A. Gordon, J. M. Simpson, G. K. Sharland, E. T. Jaeggi, J. Smallhorn, E. D. Silverman, J.-C. Fouron, G. Ryan, and L. K. Hornberger Letter Regarding Article by Jaeggi et al, "Transplacental Fetal Treatment Improves the Outcome of Prenatally Diagnosed Complete Atrioventricular Block Without Structural Heart Disease" * Response Circulation, May 10, 2005; 111(18): e287 - e288. [Full Text] [PDF]
|
|